ZP-059

Evidence outlook · lead readout

NCT04229303 · Allergic Bronchopulmonary Aspergillosis

The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.

NCT04229303: This trial was open-label with no blinding and no placebo control, splitting a modest number of participants into several small dosing cohorts of 6 to 8 people whose only formal endpoint was the adverse-event rate; there was no controlled comparison capable of showing an effect on the underlying disease.